시장보고서
상품코드
1150065

세계의 간암 시장-시장 점유율, 규모, 동향, 산업 분석 : 유형별, 치료 유형별, 지역별, 부문 예측(2022-2030년)

Liver Cancer Market Share, Size, Trends, Industry Analysis Report, By Type (Cholangio Carcinoma, Hepatocellular Carcinoma, Hepatoblastoma, Others); By Treatment Type; By Region; Segment Forecast, 2022 - 2030

발행일: | 리서치사: Polaris Market Research | 페이지 정보: 영문 116 Pages | 배송안내 : 1-2일 (영업일 기준)

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 간암 시장 규모는 2030년까지 104억 8,000만 달러에 달할 것으로 예측되고 있습니다.

세계의 간암(Liver Cancer) 시장을 조사했으며, 시장 개요/시장 규모 및 예측/동향/촉진 요인·억제 요인/유형별·치료 유형별·지역별 분석/기업 개요 등 를 제공합니다.

목차

제1장 소개

  • 리포트 설명
    • 조사의 목적
    • 시장 범위
    • 전제 조건
  • 이해관계자

제2장 주요 요약

  • 시장의 하이라이트

제3장 조사 방법

  • 개요
    • 데이터 마이닝
  • 정보원
    • 1차 정보
    • 2차 정보

제4장 세계의 간암 시장 통찰

  • 간암 시장-산업 스냅샷
  • 간암 시장 역학
    • 촉진 요인과 기회
    • 억제 요인과 과제
  • Porter’s Five Forces
    • 공급기업의 협상력
    • 신규 참가자의 위협
    • 구매자의 협상력
    • 대체품의 위협
    • 기존 기업 간의 경쟁력
  • PESTLE 분석
  • 간암 산업의 동향
  • 밸류체인 분석
  • COVID-19 영향 분석

제5장 세계의 간암 시장 : 유형별

  • 주요 조사 결과
  • 소개
    • 세계의 간암, 유형별(2018-2030년)
  • 간세포암
    • 세계의 간암 시장, 간세포암별, 지역별(2018-2030년)
  • 담관암
    • 세계의 간암 시장, 담관암별, 지역별(2018-2030년)
  • 간모 세포
    • 세계의 간암 시장, 간모 세포별, 지역별(2018-2030년)
  • 기타
    • 세계의 간암 시장, 기타별, 지역별(2018-2030년)

제6장 세계의 간암 시장 : 치료 유형별

  • 주요 조사 결과
  • 소개
    • 세계의 간암 시장, 치료 유형별(2018-2030년)
  • 표적 약물 요법
    • 세계의 간암 시장, 표적 약물 요법별, 지역별(2018-2030년)
  • 면역요법
    • 세계의 간암 시장, 면역요법별, 지역별(2018-2030년)
  • 화학요법
    • 세계의 간암 시장, 화학요법별, 지역별(2018-2030년)

제7장 세계의 간암 시장 : 지역별

  • 주요 조사 결과
  • 소개
    • 간암 시장의 평가, 지역별(2018-2030년)
  • 간암 시장-북미
    • 북미 : 간암 시장, 치료 유형별(2018-2030년)
    • 북미 : 간암 시장, 유형별(2018-2030년)
    • 간암 시장-미국
    • 간암 시장-캐나다
  • 간암 시장-유럽
    • 유럽 : 간암 시장, 치료 유형별(2018-2030년)
    • 유럽 : 간암 시장, 유형별(2018-2030년)
    • 간암 시장-영국
    • 간암 시장-프랑스
    • 간암 시장-독일
    • 간암 시장-이탈리아
    • 간암 시장-스페인
    • 간암 시장-네덜란드
    • 간암 시장-러시아
  • 간암 시장-아시아 태평양
    • 아시아 태평양 : 간암 시장, 치료 유형별(2018-2030년)
    • 아시아 태평양 : 간암 시장, 유형별(2018-2030년)
    • 간암 시장-중국
    • 간암 시장-인도
    • 간암 시장-말레이시아
    • 간암 시장-일본
    • 간암 시장-인도네시아
    • 간암 시장-한국
  • 간암 시장-중동·아프리카
    • 중동·아프리카 : 간암 시장, 치료 유형별(2018-2030년)
    • 중동·아프리카 : 간암 시장, 유형별(2018-2030년)
    • 간암 시장-사우디 아라비아
    • 간암 시장-아랍 에미리트 연방
    • 간암 시장-이스라엘
    • 간암 시장-남아프리카
  • 간암 시장-남미
    • 남미 : 간암 시장, 치료 유형별(2018-2030년)
    • 남미 : 간암 시장, 유형별(2018-2030년)
    • 간암 시장-멕시코
    • 간암 시장-브라질
    • 간암 시장-아르헨티나

제8장 경쟁 상황

  • 확대·인수 분석
    • 확대
    • 인수
  • 파트너십/협업/협정/전시

제9장 기업 개요

  • Abbott Laboratories
  • Roche
  • Bayer AG
  • Bristol Myers Squibb Company
  • Celsion Corporation
  • Eisai Co.
  • Exelixis
  • Eli Lilly
  • Qiagen NV
  • Merck
  • Pfizer
  • AbbVie
  • Amgen
  • Thermo Fisher Scientific
  • AstraZeneca
  • Johnson & Johnson
  • Sanofi SA
  • Novartis AG
LYJ 22.11.30

The global liver cancer market size is expected to reach USD 10.48 billion by 2030, according to a new study by Polaris Market Research. The report "Liver Cancer Market Share, Size, Trends, Industry Analysis Report, By Type (Cholangio Carcinoma, Hepatocellular Carcinoma, Hepatoblastoma, Others); By Treatment Type; By Region; Segment Forecast, 2022 - 2030" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The main drivers influencing the market growth are the rising incidence of liver cancer, increased investments in research & development to create novel medicines, and government programmers to raise cancer awareness. For instance, the Globocan 2020 study estimates that approximately 905,677 new cases of liver cancer were detected worldwide.

Moreover, according to Cancer Research UK, there are around 6,200 new liver cancer cases in the UK each year, or 17 cases every day. With 2% of all new cancer cases, liver cancer is the 18th most prevalent malignancy in the UK. Liver cancer is the 20th most prevalent cancer in women in the UK, with about 2,100 new cases per year.

Additionally, the market is anticipated to rise due to rising research initiatives and funding, which might lead to the developing of an innovative liver cancer treatment if these studies have successful outcomes. For instance, according to Clinical Trial.gov, NETRIS Pharma and University Hospital, Grenoble collaborated to study on September 23, 2022, will assess the safety of the association of NP137 with the standard of care Atezolizumab-Bevacizumab in the first-line setting in patients with unresectable hepatocellular carcinoma.

The NP137 study medication is being evaluated with atezolizumab-bevacizumab to improve tumor response and survival outcomes while maintaining acceptable safety. The trial officially began in November 2022 and is scheduled to end in November 2024.

Furthermore, a researcher from Australia's Edith Cowan University got USD 2.35 million in funding to support a new type of radiation treatment for liver cancer that will be trialed across Australia over the next five years. Due to the increasing prevalence of liver cancer and associated risk factors and continuous research and development efforts, the market is anticipated to rise rapidly throughout the forecast period.

But throughout the projection period, expansion in the market is anticipated to be constrained by elements including side effects linked to specific pharmaceuticals, the high price of cancer therapies, and strict regulatory environments.

Liver Cancer Market Report Highlights

In 2021, hepatocellular carcinoma is expected to rule the liver cancer market. Technological advancement, personalized medicine, and cost-effective treatment options are factors that are anticipated to boost the expansion of the global market for hepatocellular carcinoma treatments.

In 2021, the targeted medication therapy category will account for the greatest share of the market. Targeted therapy is proving to be a viable prospective treatment with promising therapeutic effects in a number of cancers.

In 2021, the North America accounted for the largest revenue share in 2021. The main factors influencing market expansion in North America are the rising incidence of liver cancer in the area, the presence of sizable market participants, and the development of novel products.

The global players with global presence include Abbott Laboratories, F. Hoffmann-La Roche, Bayer AG, Bristol Myers Squibb Company, and Celsion Corporation.

Polaris Market Research has segmented the Liver Cancer Market report based on, type, treatment type, and region:

Liver Cancer, Type Outlook (Revenue - USD Billion, 2018 - 2030)

Hepatocellular Carcinoma

Cholangio Carcinoma

Hepatoblastoma

Other Types

Liver Cancer, Treatment Type Outlook (Revenue - USD Billion, 2018 - 2030)

Targeted Drug Therapy

Immunotherapy

Chemotherapy

Liver Cancer, Regional Outlook (Revenue - USD Billion, 2018 - 2030)

North America

U.S

Canada

Europe

Germany

UK

France

Italy

Spain

Russia

Netherlands

Asia Pacific

China

India

Japan

South Korea

Indonesia

Malaysia

Latin America

Argentina

Brazil

Mexico

Middle East & Africa

UAE

Saudi Arabia

Israel

South Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Liver Cancer Market Insights

  • 4.1. Liver Cancer Market - Industry Snapshot
  • 4.2. Liver Cancer Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Increasing prevalence of liver cancer
      • 4.2.1.2. Rising initiatives undertaken by public and private organizations
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. High cost of diagnostic imaging
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTLE Analysis
  • 4.5. Liver Cancer Industry trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Liver Cancer Market, by Type

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Liver Cancer, by Type, 2018 - 2030 (USD Billion)
  • 5.3. Hepatocellular Carcinoma
    • 5.3.1. Global Liver Cancer Market, by Hepatocellular Carcinoma, by Region, 2018 - 2030 (USD Billion)
  • 5.4. Cholangio Carcinoma
    • 5.4.1. Global Liver Cancer Market, by Cholangio Carcinoma, by Region, 2018 - 2030 (USD Billion)
  • 5.5. Hepatoblastoma
    • 5.5.1. Global Liver Cancer Market, by Hepatoblastoma, by Region, 2018 - 2030 (USD Billion)
  • 5.6. Others
    • 5.6.1. Global Liver Cancer Market, by Others, by Region, 2018 - 2030 (USD Billion)

6. Global Liver Cancer Market, by Treatment Type

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
  • 6.3. Targeted Drug Therapy
    • 6.3.1. Global Liver Cancer Market, by Targeted Drug Therapy, by Region, 2018 - 2030 (USD Billion)
  • 6.4. Immunotherapy
    • 6.4.1. Global Liver Cancer Market, by Immunotherapy, by Region, 2018 - 2030 (USD Billion)
  • 6.5. Chemotherapy
    • 6.5.1. Global Liver Cancer Market, by Chemotherapy, by Region, 2018 - 2030 (USD Billion)

7. Global Liver Cancer Market, by Geography

  • 7.1. Key findings
  • 7.2. Introduction
    • 7.2.1. Liver Cancer Market Assessment, By Geography, 2018 - 2030 (USD Billion)
  • 7.3. Liver Cancer Market - North America
    • 7.3.1. North America: Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
    • 7.3.2. North America: Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)
    • 7.3.3. Liver Cancer Market - U.S.
      • 7.3.3.1. U.S.: Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
      • 7.3.3.2. U.S.: Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)
    • 7.3.4. Liver Cancer Market - Canada
      • 7.3.4.1. Canada: Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
      • 7.3.4.2. Canada: Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)
  • 7.4. Liver Cancer Market - Europe
    • 7.4.1. Europe: Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
    • 7.4.2. Europe: Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)
    • 7.4.3. Liver Cancer Market - UK
      • 7.4.3.1. UK: Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
      • 7.4.3.2. UK: Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)
    • 7.4.4. Liver Cancer Market - France
      • 7.4.4.1. France: Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
      • 7.4.4.2. France: Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)
    • 7.4.5. Liver Cancer Market - Germany
      • 7.4.5.1. Germany: Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
      • 7.4.5.2. Germany: Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)
    • 7.4.6. Liver Cancer Market - Italy
      • 7.4.6.1. Italy: Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
      • 7.4.6.2. Italy: Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)
    • 7.4.7. Liver Cancer Market - Spain
      • 7.4.7.1. Spain: Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
      • 7.4.7.2. Spain: Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)
    • 7.4.8. Liver Cancer Market - Netherlands
      • 7.4.8.1. Netherlands: Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
      • 7.4.8.2. Netherlands: Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)
    • 7.4.9. Liver Cancer Market - Russia
      • 7.4.9.1. Russia: Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
      • 7.4.9.2. Russia: Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)
  • 7.5. Liver Cancer Market - Asia Pacific
    • 7.5.1. Asia Pacific: Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
    • 7.5.2. Asia Pacific: Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)
    • 7.5.3. Liver Cancer Market - China
      • 7.5.3.1. China: Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
      • 7.5.3.2. China: Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)
    • 7.5.4. Liver Cancer Market - India
      • 7.5.4.1. India: Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
      • 7.5.4.2. India: Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)
    • 7.5.5. Liver Cancer Market - Malaysia
      • 7.5.5.1. Malaysia: Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
      • 7.5.5.2. Malaysia: Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)
    • 7.5.6. Liver Cancer Market - Japan
      • 7.5.6.1. Japan: Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
      • 7.5.6.2. Japan: Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)
    • 7.5.7. Liver Cancer Market - Indonesia
      • 7.5.7.1. Indonesia: Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
      • 7.5.7.2. Indonesia: Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)
    • 7.5.8. Liver Cancer Market - South Korea
      • 7.5.8.1. South Korea: Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
      • 7.5.8.2. South Korea: Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)
  • 7.6. Liver Cancer Market - Middle East & Africa
    • 7.6.1. Middle East & Africa: Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
    • 7.6.2. Middle East & Africa: Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)
    • 7.6.3. Liver Cancer Market - Saudi Arabia
      • 7.6.3.1. Saudi Arabia: Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
      • 7.6.3.2. Saudi Arabia: Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)
    • 7.6.4. Liver Cancer Market - UAE
      • 7.6.4.1. UAE: Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
      • 7.6.4.2. UAE: Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)
    • 7.6.5. Liver Cancer Market - Israel
      • 7.6.5.1. Israel: Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
      • 7.6.5.2. Israel: Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)
    • 7.6.6. Liver Cancer Market - South Africa
      • 7.6.6.1. South Africa: Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
      • 7.6.6.2. South Africa: Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)
  • 7.7. Liver Cancer Market - Latin America
    • 7.7.1. Latin America: Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
    • 7.7.2. Latin America: Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)
    • 7.7.3. Liver Cancer Market - Mexico
      • 7.7.3.1. Mexico: Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
      • 7.7.3.2. Mexico: Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)
    • 7.7.4. Liver Cancer Market - Brazil
      • 7.7.4.1. Brazil: Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
      • 7.7.4.2. Brazil: Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)
    • 7.7.5. Liver Cancer Market - Argentina
      • 7.7.5.1. Argentina: Liver Cancer Market, by Treatment Type, 2018 - 2030 (USD Billion)
      • 7.7.5.2. Argentina: Liver Cancer Market, by Type, 2018 - 2030 (USD Billion)

8. Competitive Landscape

  • 8.1. Expansion and Acquisition Analysis
    • 8.1.1. Expansion
    • 8.1.2. Acquisitions
  • 8.2. Partnerships/Collaborations/Agreements/Exhibitions

9. Company Profiles

  • 9.1. Abbott Laboratories
    • 9.1.1. Company Overview
    • 9.1.2. Financial Performance
    • 9.1.3. Product Benchmarking
    • 9.1.4. Recent Development
  • 9.2. Roche
    • 9.2.1. Company Overview
    • 9.2.2. Financial Performance
    • 9.2.3. Product Benchmarking
    • 9.2.4. Recent Development
  • 9.3. Bayer AG
    • 9.3.1. Company Overview
    • 9.3.2. Financial Performance
    • 9.3.3. Product Benchmarking
    • 9.3.4. Recent Development
  • 9.4. Bristol Myers Squibb Company
    • 9.4.1. Company Overview
    • 9.4.2. Financial Performance
    • 9.4.3. Product Benchmarking
    • 9.4.4. Recent Development
  • 9.5. Celsion Corporation
    • 9.5.1. Company Overview
    • 9.5.2. Financial Performance
    • 9.5.3. Product Benchmarking
    • 9.5.4. Recent Development
  • 9.6. Eisai Co.
    • 9.6.1. Company Overview
    • 9.6.2. Financial Performance
    • 9.6.3. Product Benchmarking
    • 9.6.4. Recent Development
  • 9.7. Exelixis
    • 9.7.1. Company Overview
    • 9.7.2. Financial Performance
    • 9.7.3. Product Benchmarking
    • 9.7.4. Recent Development
  • 9.8. Eli Lilly
    • 9.8.1. Company Overview
    • 9.8.2. Financial Performance
    • 9.8.3. Product Benchmarking
    • 9.8.4. Recent Development
  • 9.9. Qiagen N.V
    • 9.9.1. Company Overview
    • 9.9.2. Financial Performance
    • 9.9.3. Product Benchmarking
    • 9.9.4. Recent Development
  • 9.10. Merck
    • 9.10.1. Company Overview
    • 9.10.2. Financial Performance
    • 9.10.3. Product Benchmarking
    • 9.10.4. Recent Development
  • 9.11. Pfizer
    • 9.11.1. Company Overview
    • 9.11.2. Financial Performance
    • 9.11.3. Product Benchmarking
    • 9.11.4. Recent Development
  • 9.12. AbbVie
    • 9.12.1. Company Overview
    • 9.12.2. Financial Performance
    • 9.12.3. Product Benchmarking
    • 9.12.4. Recent Development
  • 9.13. Amgen
    • 9.13.1. Company Overview
    • 9.13.2. Financial Performance
    • 9.13.3. Product Benchmarking
    • 9.13.4. Recent Development
  • 9.14. Thermo Fisher Scientific
    • 9.14.1. Company Overview
    • 9.14.2. Financial Performance
    • 9.14.3. Product Benchmarking
    • 9.14.4. Recent Development
  • 9.15. AstraZeneca
    • 9.15.1. Company Overview
    • 9.15.2. Financial Performance
    • 9.15.3. Product Benchmarking
    • 9.15.4. Recent Development
  • 9.16. Johnson & Johnson
    • 9.16.1. Company Overview
    • 9.16.2. Financial Performance
    • 9.16.3. Product Benchmarking
    • 9.16.4. Recent Development
  • 9.17. Sanofi SA
    • 9.17.1. Company Overview
    • 9.17.2. Financial Performance
    • 9.17.3. Product Benchmarking
    • 9.17.4. Recent Development
  • 9.18. Novartis AG
    • 9.18.1. Company Overview
    • 9.18.2. Financial Performance
    • 9.18.3. Product Benchmarking
    • 9.18.4. Recent Development
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제